YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Effect of Fluvastatin on the Pharmacokinetics of Diltiazem and its Metabolite, Desacetyldiltiazem in Rats

흰쥐에서 플루바스타틴이 딜티아젬 및 그 대사체인 데스아세틸딜티아젬의 약물동태에 미치는 영향

  • Published : 2006.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

The aim of this study was to investigate the effect of fluvastatin on the pharmacokinetics of diltiazem and its active metabolite, desacetyldiltiazem, in rats. Pharmacokinetic parameters of diltiazem and desacetyldiltiazem were deter-mined after an oral administration of diltiazem (15 mg/kg) to rats pretreated with fluvastatin (0.5 and 1.5 mg/kg). Compared with the control (given diltiazem alone), the pretreatment of fluvastatin significantly (p<0.05) increased the area under the plasma concentration (AUC), peak plasma concentration $(C_{max})\;and\;K_a$ of diltiazem. Relative bioavailability $(RB\%)$ of diltiazem increased from 1.36- to 1.55-fold. However there were no significant changes in $t_{max},\;K_{el}\;and\;t_{1/2}$ of diltiazem. The pretreatment of fluvastatin also altered the pharmacokintic parameters of desacetyldiltiazem. The pretreatment of fluvastatin (1.5 mg/kg) significantly (p<0.05) increased the AUC of desacetyldiltiazem, whereas the metabolite parent ratio (MR) of desacetyldiatlazem was decreased significantly (p<0.05), suggesting that fluvastatin might inhibit the metabolism of diltiazem. The pretreatment of fluvastatin enhanced the bioavailability of diltiazem in a dose dependent manner at doses ranging from 0.5 to 1.5 mg/kg. further studies for the drug Interaction will be needed in the clinical trials when dilitazem is administrated concomitantly with fluvastatin in humans.

Keywords

References

  1. Chaffman, M. and Brogden, R. N. : Diltiazem: a review of its pharmacological properties and therapeutic efficacy. Drugs. 29, 387 (1985) https://doi.org/10.2165/00003495-198529050-00001
  2. Weir, M. R. : Diltiazem ten years of clinical experience in the treatment of hypertension. J. Clin. Pharmacol. 35, 220 (1995) https://doi.org/10.1002/j.1552-4604.1995.tb04051.x
  3. Yeung, P. K., Prescott, C., Haddad, C., Montague, T. J., McGregor, C., Quilliam, M. A., Xei, M., Li, R., Farmer, P. and Klassen, G. A. : Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose. Eur. J. Drug. Metab. Pharmacokinet. 18, 199 (1993) https://doi.org/10.1007/BF03188796
  4. Scholz, H. : Pharmacological aspects of calcium channel blockers. Cardiovas. Drugs Ther. 10, 869 (1997) https://doi.org/10.1007/BF00051613
  5. Epstein, M., Loutzenhister, R. D. : Effects of calcium antagonists on renal hemodynamics. Am. J. Kidney Dis. 16, 10 (1990)
  6. Ruilope, L. M. and Alcaar, J. M. : Renal effects of calcium entry blockers. Cardiovas. Drugs Ther. 4, 979 (1990) https://doi.org/10.1007/BF02018304
  7. Sterzel, P. B. : Renal actions of calcium antagonists. J. Cardiovas. Pharmacol. 10, 17 (1987) https://doi.org/10.1097/00005344-198706107-00004
  8. Eichelbaum, M. and Echizen, H. : Clinical pharmacology of calcium antagonists: A critical review. J. Cardiovas. Pharmacol. 6, 963 (1984) https://doi.org/10.1097/00005344-198400067-00006
  9. Bianchetti, G., Regazzi, M., Rondanelli, R., Ascalone, V. and Morselli, P. L. : Bioavailability of diltiazem as a function of the administered dose. Biopharm. Drug Dispos. 12, 391 (1991) https://doi.org/10.1002/bdd.2510120508
  10. Klaassen, C. D. : Toxicology. 5th ed. New York: McGraw-Hill. 113 (1999)
  11. Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T. and Guzelian, P. S. : Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80, 1029 (1987) https://doi.org/10.1172/JCI113156
  12. Kolars, J. C., Schmiedlin-Ren, P., Dobbins, W. O. 3rd., Schuetz, J., Wrighton, S. A. and Watkins, P. B. : Heterogeneity of cytochrome P450IIIA expression in rat. gut epithelia. Gastroenterology 102, 1186 (1992) https://doi.org/10.1016/0016-5085(92)90756-O
  13. Lefebvre, M., Homsy, W., Caille, G. and du Souich, P. : Firstpass metabolism of diltiazem in anesthetized rabbits: Role of extrahepatic organs. Pharm. Res. 13, 124 (1996) https://doi.org/10.1023/A:1016097805003
  14. Homsy, W., Caille, G. and du Souich, P. : The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit. Pharm. Res. 12, 1722 (1995) https://doi.org/10.1023/A:1016217822770
  15. Homsy, W., Lefebvre, M., Caille, G. and du Souich, P. : Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits: In vitro studies. Pharm. Res. 12, 609 (1995) https://doi.org/10.1023/A:1016226601988
  16. Yusa, K. and Tsuruo, T. : Reversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to Pglycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49, 5002 (1989)
  17. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. : P-glycoprotein-mediated transcellular transport of MDRreversing agents. FEBS Lett. 324, 99 (1993) https://doi.org/10.1016/0014-5793(93)81540-G
  18. Chaudhary, P. M. and Robinson, I. B. : Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 66, 85 (1991) https://doi.org/10.1016/0092-8674(91)90141-K
  19. Van Asperen, J., Van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijen, W. J. and Beijnen, J. H. : Enhanced oral bilavailability of diltiazem in mice treated with the pglycoprotein blocker SDZ PSC 833. Br. J. Cancer 76, 1181 (1997) https://doi.org/10.1038/bjc.1997.530
  20. Biedler, J. L. and Riehm, H. : Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30, 1174 (1970)
  21. Ford, J. M. : Modulators of multidrug resistancepreclinical studies. Hematol. Oncol. Clin. N. Am. 9, 337 (1995)
  22. Fruehauf, J. P. and Manetta, A. : Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDR1 expression. Contrib. Gynecol. Obstet. 19, 39 (1994)
  23. Plosker, G. L. and Wagstaff, A. J. : Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs. 51, 433 (1996) https://doi.org/10.2165/00003495-199651030-00011
  24. Schectman, G. and Hiatt, J. : Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann. Intern. Med. 125, 990 (1996) https://doi.org/10.7326/0003-4819-125-12-199612150-00011
  25. Langtry, H. D. and Markham, A. : Fluvastatin: a review of its use in lipid disorders. Drugs. 57, 583 (1999) https://doi.org/10.2165/00003495-199957040-00009
  26. Jean-Paul, D. : Clinical implications of the biopharmaceutical properties of fluvastatin. The American Journal of Cardiology 73, 12 (1994)
  27. Fische, V., Johanson, L. and Heitzl, F. : The 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug. Metab. Dispos. 27, 410 (1999)
  28. Cohen, L. H., van Leeuwen, R. E., van Thiel, G. C. van Pelt, J. F. and Yap, S. H. : Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm. Drug. Dispos. 21, 353 (2000) https://doi.org/10.1002/bdd.249
  29. Kirchheiner, J. and Brockmoller, J. : Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77, 1 (2005) https://doi.org/10.1016/j.clpt.2004.08.009
  30. Kirchheiner, J., Kudlicz, D., Meisel, C., Bauer, S., Meineke, I., Roots, I. and Brockmöller, J. : Influence of CYP 2C9 polymorphisms on the pharmacokinetics and cholesterollowering activity of (-)-3s,5r-fluvastatin and (+)-3r,5s-fluvastatin in healthy volunteers. Clinical Pharmacology & Therapeutics. 74, 186 (2003) https://doi.org/10.1016/S0009-9236(03)00121-8
  31. Yeo, K. R. and Yeo, W. W. : Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br. J. Clin. Pharmacol. 51, 461 (2001) https://doi.org/10.1046/j.1365-2125.2001.01386.x
  32. Watanabe, H., Kosuge, K., Nishio, S., Yamada, H., Uchida, S., Satoh, H., Hayashi, H., Ishizaki, T. and Ohashi, K. : Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci. 76, 281 (2004) https://doi.org/10.1016/j.lfs.2004.06.022
  33. Bogman, K., Peyer, A. K., Torok, M., Kusters, E. and Drewe, J. : HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol. 132, 1183 (2001) https://doi.org/10.1038/sj.bjp.0703920
  34. Ehrhardt, M., Lindenmaier, H., Burhenne, J., Haefeli, W. E. and Weiss, J. : Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochemical Pharmacology 67, 285 (2004) https://doi.org/10.1016/j.bcp.2003.09.008
  35. Goebel, K. J. and Kolle, E. U. : High performance liquid chromatographic dertermination of diltiazem and four of its metabolites in plasma. J. Chromatogr. 345, 355 (1985) https://doi.org/10.1016/0378-4347(85)80172-9
  36. Rocci, M. L. and Jusko, W. J. : LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine. 16, 203 (1983) https://doi.org/10.1016/0010-468X(83)90082-X
  37. Mc Donnell, C. G., Shorten, G. and Van Pelt, F. N. : Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia. 60, 747 (2005) https://doi.org/10.1111/j.1365-2044.2005.04110.x